Growth hormone

Sermorelin acetate

Sermorelin · GRF(1–29) amide

Sermorelin is associated with the amidated GRF(1–29) fragment. The acetate designation belongs to the product chemical form and should remain in its specification.

Reviewed September 2026

Residues
29. verified: 29 peptide-chain residues, with C-terminal amidation; acetate is not a residue.
Average mass
3,357.9 Da. verified: Reference form: Sermorelin peptide moiety, GRF(1–29)-NH2; acetate salt stoichiometry/hydration is not specified, so the reference mass excludes acetate and water of hydration.; formula C149H246N44O42S. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
pI
Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.

Reference details

Reference details
Residues29
Average mass3,357.9 Da
pINot established
Identity
AliasesSermorelin, GRF(1–29) amide
Research areaGrowth hormone

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

Sermorelin peptide moiety, GRF(1–29)-NH2; acetate salt stoichiometry/hydration is not specified, so the reference mass excludes acetate and water of hydration. Reference only, not a sold-lot measurement.

  • Residues: 29 (verified). 29 peptide-chain residues, with C-terminal amidation; acetate is not a residue. Residues source 1 Residues source 2
  • Average mass: 3,357.9 Da (verified). Reference form: Sermorelin peptide moiety, GRF(1–29)-NH2; acetate salt stoichiometry/hydration is not specified, so the reference mass excludes acetate and water of hydration.; formula C149H246N44O42S. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
  • pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1

Reference scope and linked records

Reference type: Amidated peptide; acetate product context.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: Sermorelin Acetate. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Stimulation of GH secretion with GRF1-44, GRF1-40 and GRF1-29 in normal subjects. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About Sermorelin acetate

Identity and context

A fragment of a releasing hormone is not growth hormone itself. It also differs from the albumin-conjugating CJC-1295 analogue and from tesamorelin. Shared use of growth hormone release as an experimental endpoint does not make these structures equivalent.

Reference classification

Amidated peptide; acetate product context. The linked catalogue product is Sermorelin Acetate. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Confirm fragment length, sequence, C-terminal amidation and acetate content. A quoted molecular mass for the peptide moiety should not be mistaken for a fully specified salt or hydrate composition.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesAn early primary physiology study compared GRF peptides of different lengths in healthy volunteers and measured GH responses. The short GRF(1–29) peptide produced a response in that experiment. The small study is useful background for releasing-factor biology, not a comprehensive assessment of long-term outcomes.Source context
What cannot be inferredThe paper does not authenticate Sermorelin Acetate from Aminos or establish equivalence to a pharmaceutical preparation. A biomarker response in a small physiology experiment is not a clinical recommendation.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Stimulation of GH secretion with GRF1-44, GRF1-40 and GRF1-29 in normal subjectsPrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.